Metrics as of 10/13/2026, 06:39 PM (Berlin time), refresh in progress.
Tempest Therapeutics Stock
Tempest Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Matthew Angel
- Employees
- 4
- Market cap
- $11 M
- IPO
- 12/11/2012
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors…
Tempest Therapeutics stock: price history
1D
-8.3%
1W
-13.5%
1M
-16.1%
6M
-69.7%
YTD
-76.3%
1Y
-94.1%
2Y
-94.9%
5Y
-99.7%
10Y
-100.0%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~16% weaker price swings than usual
Ask the agents about Tempest Therapeutics
Analyst assessment of Tempest Therapeutics
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 24/09/2026
Tempest Therapeutics stock metrics
P/E
-0.15
P/B
-9.52
EV/EBITDA
-0.44
RETURN ON EQUITY
481.1%
NET MARGIN
0.0%
DEBT/EQUITY
-6.94
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
60.1%
FLOAT SHARES
9,606,511
AVG. DAILY VOLUME (30D)
5,255,420
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Tempest Therapeutics stock
What does Tempest Therapeutics do?
Tempest Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Matthew Angel, the company employs around 4 people.
The IPO was on 12/11/2012; the stock trades on NASDAQ under the ticker TPST.
What do analysts say about Tempest Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
This is an external assessment, not a statement by Market Jury.
When does Tempest Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -16% stronger than usual.
Does Tempest Therapeutics pay a dividend?
No, Tempest Therapeutics currently does not pay a dividend.
Which stocks are comparable to Tempest Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Tempest Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Tempest Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.